Lona L Christrup

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4372629/publications.pdf

Version: 2024-02-01

		218662	168376
87	3,061	26	53
papers	citations	h-index	g-index
90	90	90	3177
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Oral absorption of oxycodone in patients with short bowel syndrome. Scandinavian Journal of Gastroenterology, 2021, 56, 1023-1029.	1.5	1
2	Effect of Rouxâ€enâ€Y gastric bypass on the pharmacokineticâ€pharmacodynamic relationships of liquid and controlledâ€release formulations of oxycodone. Basic and Clinical Pharmacology and Toxicology, 2021, 129, 232-245.	2.5	3
3	Population pharmacokineticâ€pharmacodynamic modelling of liquid and controlledâ€release formulations of oxycodone in healthy volunteers. Basic and Clinical Pharmacology and Toxicology, 2020, 126, 263-276.	2.5	13
4	Chronic abdominal pain and persistent opioid use after bariatric surgery. Scandinavian Journal of Pain, 2020, 20, 239-251.	1.3	15
5	Differences in Kidney Function Estimates Based on Creatinine and/or Cystatin C in Non-Traumatic Amputation Patients and Their Impact on Drug Prescribing. Journal of Clinical Medicine, 2019, 8, 89.	2.4	6
6	Healthcare professionals' agreement on clinical relevance of drug-related problems among elderly patients. International Journal of Clinical Pharmacy, 2018, 40, 119-125.	2.1	4
7	Association Between Genetic Polymorphisms and Pain Sensitivity in Patients with Hip Osteoarthritis. Pain Practice, 2018, 18, 587-596.	1.9	25
8	Recreational drug use at a major music festival: trend analysis of anonymised pooled urine. Clinical Toxicology, 2018, 56, 245-255.	1.9	13
9	Creatinine-Based Renal Function Estimates and Dosage of Postoperative Pain Management for Elderly Acute Hip Fracture Patients. Pharmaceuticals, $2018,11,88.$	3.8	6
10	Offset Analgesia and The Impact of Treatment with Oxycodone and Venlafaxine: A Placeboâ€Controlled, Randomized Trial in Healthy Volunteers. Basic and Clinical Pharmacology and Toxicology, 2018, 123, 727-731.	2.5	12
11	Genetic Influences of <i><scp>OPRM</scp>1</i> , <i><scp>OPRD</scp>1</i> and <i><scp>COMT</scp></i> on Morphine Analgesia in a Multiâ€Modal, Multiâ€Tissue Human Experimental Pain Model. Basic and Clinical Pharmacology and Toxicology, 2017, 121, 6-12.	2.5	18
12	Analysis of opioid consumption in clinical trials: a simulation based analysis of power of four approaches. Journal of Pharmacokinetics and Pharmacodynamics, 2017, 44, 325-333.	1.8	4
13	Objective methods for the assessment of the spinal and supraspinal effects of opioids. Scandinavian Journal of Pain, 2017, 14, 15-24.	1.3	13
14	Cortical and spinal assessment - a comparative study using encephalography and the nociceptive withdrawal reflex. Journal of Pharmacological and Toxicological Methods, 2017, 84, 37-43.	0.7	3
15	Association between Gene Polymorphisms and Pain Sensitivity Assessed in a Multiâ€Modal Multiâ€Tissue Human Experimental Model – An Explorative Study. Basic and Clinical Pharmacology and Toxicology, 2016, 119, 360-366.	2.5	8
16	Definition, diagnosis and treatment strategies for opioid-induced bowel dysfunctionâ€"Recommendations of the Nordic Working Group. Scandinavian Journal of Pain, 2016, 11, 111-122.	1.3	73
17	A Pharmacokinetic-Pharmacodynamic Model of Morphine Exposure and Subsequent Morphine Consumption in Postoperative Pain. Pharmaceutical Research, 2016, 33, 1093-1103.	3.5	13
18	A Model-Based Approach for Joint Analysis of Pain Intensity and Opioid Consumption in Postoperative Pain. AAPS Journal, 2016, 18, 1013-1022.	4.4	4

#	Article	IF	Citations
19	Short-term oxycodone treatment does not affect electrogenic ion transport in isolated mucosa from the human rectosigmoid colon. Scandinavian Journal of Gastroenterology, 2016, 51, 538-547.	1.5	2
20	Repeated Time-to-event Analysis of Consecutive Analgesic Events in Postoperative Pain. Anesthesiology, 2015, 123, 1411-1419.	2.5	28
21	Exploratory survey study of long-term users of nicotine replacement therapy in Danish consumers. Harm Reduction Journal, 2015, 12, 2.	3.2	5
22	Symptoms and side effects in chronic nonâ€cancer pain patients: clinical implications and development of new assessment tools. Acta Anaesthesiologica Scandinavica, 2015, 59, 1060-1067.	1.6	0
23	Association Between Human Painâ€Related Genotypes and Variability in Opioid Analgesia: An Updated Review. Pain Practice, 2015, 15, 580-594.	1.9	56
24	Disruption of Cortical Connectivity during Remifentanil Administration Is Associated with Cognitive Impairment but Not with Analgesia. Anesthesiology, 2015, 122, 140-149.	2.5	15
25	Population pharmacokinetics of morphine and morphine-6-glucuronide following rectal administration – A dose escalation study. European Journal of Pharmaceutical Sciences, 2015, 68, 78-86.	4.0	8
26	Objective markers of the analgesic response to morphine in experimental pain research. Journal of Pharmacological and Toxicological Methods, 2015, 73, 7-14.	0.7	7
27	A review of morphine and morphine-6-glucuronide's pharmacokinetic–pharmacodynamic relationships in experimental and clinical pain. European Journal of Pharmaceutical Sciences, 2015, 74, 45-62.	4.0	92
28	Does mutual compensation of the cognitive effects induced by pain and opioids exist? An experimental study. Psychopharmacology, 2015, 232, 1373-1381.	3.1	10
29	Altered Frequency Distribution in the Electroencephalogram is Correlated to the Analgesic Effect of Remifentanil. Basic and Clinical Pharmacology and Toxicology, 2015, 116, 414-422.	2.5	17
30	A cortical source localization analysis of resting EEG data after remifentanil infusion. Clinical Neurophysiology, 2015, 126, 898-905.	1.5	10
31	Modelling concentration–analgesia relationships for morphine to evaluate experimental pain models. European Journal of Pharmaceutical Sciences, 2015, 66, 50-58.	4.0	10
32	Pharmacodynamic Modelling of Placebo and Buprenorphine Effects on Eventâ€Related Potentials in Experimental Pain. Basic and Clinical Pharmacology and Toxicology, 2014, 115, 343-351.	2.5	4
33	Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study. Pharmacogenetics and Genomics, 2014, 24, 185-194.	1.5	42
34	Quality of life and symptoms in patients with malignant diseases admitted to a comprehensive cancer centre. Supportive Care in Cancer, 2014, 22, 1843-1849.	2.2	11
35	Pharmacokinetic–Pharmacodynamic Modelling of the Analgesic and Antihyperalgesic Effects of Morphine after Intravenous Infusion in Human Volunteers. Basic and Clinical Pharmacology and Toxicology, 2014, 115, 257-267.	2.5	7
36	Altered cortical causality after remifentanil administration in healthy volunteers: A novel approach for pharmaco-EEG., 2014, 2014, 4290-3.		0

#	Article	IF	CITATIONS
37	Barriers to Cancer Pain Management in Danish and Lithuanian Patients Treated in Pain and Palliative Care Units. Pain Management Nursing, 2014, 15, 51-58.	0.9	13
38	Differences between opioids: pharmacological, experimental, clinical and economical perspectives. British Journal of Clinical Pharmacology, 2013, 75, 60-78.	2.4	150
39	Morphine- and buprenorphine-induced analgesia and antihyperalgesia in a human inflammatory pain model: a double-blind, randomized, placebo-controlled, five-arm crossover study. Journal of Pain Research, 2013, 6, 23.	2.0	26
40	Switching from high doses of pure $\hat{A}\mu$ -opioid agonists to transdermal buprenorphine in patients with cancer: A feasibility study. Journal of Opioid Management, 2013, 9, 255-262.	0.5	8
41	Effect of intraoral and subcutaneous morphine on dyspnea at rest in terminal patients with primary lung cancer or lung metastases. Journal of Opioid Management, 2013, 9, 269-274.	0.5	24
42	A physiologically-based recirculatory meta-model for nasal fentanyl in man. Journal of Pharmacokinetics and Pharmacodynamics, 2012, 39, 561-576.	1.8	11
43	Prediction of pain sensitivity in healthy volunteers. Journal of Pain Research, 2012, 5, 313.	2.0	37
44	Pharmacokinetic/Pharmacodynamic Relationships of Transdermal Buprenorphine and Fentanyl in Experimental Human Pain Models. Basic and Clinical Pharmacology and Toxicology, 2011, 108, 274-284.	2.5	36
45	The impact of an electronic monitoring and reminder device on patient compliance with antihypertensive therapy: a randomized controlled trial. Journal of Hypertension, 2010, 28, 194-200.	0.5	55
46	Psychological and behavioural predictors of pain management outcomes in patients with cancer. Scandinavian Journal of Caring Sciences, 2010, 24, 781-790.	2.1	19
47	A Pharmacokinetic and Pharmacodynamic Study of Oral Oxycodone in a Human Experimental Pain Model of Hyperalgesia. Clinical Pharmacokinetics, 2010, 49, 817-827.	3.5	24
48	Rationales behind the choice of administration form with fentanyl: Delphi survey among Danish general practitioners. Journal of Opioid Management, 2010, 6, 259-268.	0.5	2
49	Translational pain research: Evaluating analgesic effect in experimental visceral pain models. World Journal of Gastroenterology, 2009, 15, 177.	3.3	14
50	Survey of patient and physician assessment of a compliance reminder device in the treatment of hypertension. Blood Pressure, 2009, 18, 280-285.	1.5	0
51	Role of active metabolites in the use of opioids. European Journal of Clinical Pharmacology, 2009, 65, 121-139.	1.9	95
52	The Danish version of the Medication Adherence Report Scale: Preliminary Validation in Cancer Pain Patients. Pain Practice, 2009, 9, 1-7.	1.9	17
53	The Danish Barriers Questionnaireâ€II: Preliminary Validation in Cancer Pain Patients. Pain Practice, 2009, 9, 266-274.	1.9	11
54	Danish Pain Specialists' Rationales behind the Choice of Fentanyl Transdermal Patches and Oral Transmucosal Systemsâ€"A Delphi Study. Pain Medicine, 2009, 10, 1442-1451.	1.9	4

#	Article	IF	CITATIONS
55	Patientâ€related barriers to cancer pain management: a systematic exploratory review. Scandinavian Journal of Caring Sciences, 2009, 23, 190-208.	2.1	99
56	Survey of patient and physician assessment of a compliance reminder device in the treatment of hypertension. Blood Pressure, 2009, 18, 280-285.	1.5	7
57	Novel formulations and routes of administration for opioids in the treatment of breakthrough pain. Therapy: Open Access in Clinical Medicine, 2009, 6, 695-706.	0.2	10
58	Pharmacokinetic–Pharmacodynamic Relationships of Cognitive and Psychomotor Effects of Intravenous Buprenorphine Infusion in Human Volunteers. Basic and Clinical Pharmacology and Toxicology, 2008, 103, 94-101.	2.5	26
59	Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: A randomized, double-blind, double-dummy, two-way, crossover study. Clinical Therapeutics, 2008, 30, 469-481.	2.5	106
60	Pharmacokinetics and Pharmacodynamics of Intranasal Versus Intravenous Fentanyl in Patients with Pain after Oral Surgery. Annals of Pharmacotherapy, 2008, 42, 1380-1387.	1.9	80
61	Pharmacokineticâ€Pharmacodynamic Modeling of Morphine and Oxycodone Concentrations and Analgesic Effect in a Multimodal Experimental Pain Model. Journal of Clinical Pharmacology, 2008, 48, 619-631.	2.0	54
62	Patient acceptance of a tablet reminder device. Journal of Medical Marketing, 2007, 7, 152-161.	0.2	2
63	Differential effect of opioids in patients with chronic pancreatitis: An experimental pain study. Scandinavian Journal of Gastroenterology, 2007, 42, 383-390.	1.5	84
64	Pharmacokinetics of morphine-6-glucuronide following oral administration in healthy volunteers. European Journal of Clinical Pharmacology, 2007, 63, 761-767.	1.9	9
65	Population pharmacokinetics of buprenorphine following a two-stage intravenous infusion in healthy volunteers. European Journal of Clinical Pharmacology, 2007, 63, 1153-1159.	1.9	19
66	Physician-related barriers to cancer pain management with opioid analgesics: A systematic review. Journal of Opioid Management, 2007, 3, 207-214.	0.5	78
67	Pharmacokinetics of M6G following intravenous and oral administration in healthy volunteers. Acute Pain, 2006, 8, 63-71.	0.1	5
68	A comparative study of oxycodone and morphine in a multi-modal, tissue-differentiated experimental pain model. Pain, 2006, 123, 28-36.	4.2	138
69	Neuropsychological assessment of chronic non-malignant pain patients treated in a multidisciplinary pain centre. European Journal of Pain, 2005, 9, 453-453.	2.8	108
70	Effect of liquid volume and food intake on the absolute bioavailability of danazol, a poorly soluble drug. European Journal of Pharmaceutical Sciences, 2005, 24, 297-303.	4.0	98
71	Pharmacological consequences of long-term morphine treatment in patients with cancer and chronic non-malignant pain. European Journal of Pain, 2004, 8, 263-271.	2.8	16
72	Medicated Chewing Gum. American Journal of Drug Delivery, 2004, 2, 75-88.	0.6	28

#	Article	IF	CITATIONS
73	Relationships Among Morphine Metabolism, Pain and Side Effects During Long-Term Treatment. Journal of Pain and Symptom Management, 2003, 25, 74-91.	1.2	125
74	Changing M3G/M6G Ratios and Pharmacodynamics in a Cancer Patient During Long-Term Morphine Treatment. Journal of Pain and Symptom Management, 2002, 23, 161-164.	1.2	19
75	Steady-State Kinetics and Dynamics of Morphine in Cancer Patients. Journal of Pain and Symptom Management, 1999, 18, 164-173.	1.2	18
76	Opioid analgesics as noncompetitive N-methyl-d-aspartate (NMDA) antagonists. Biochemical Pharmacology, 1998, 56, 553-559.	4.4	149
77	Recommended use of morphine in neonates, infants and children based on a literature review: Part 1—Pharmacokinetics. Paediatric Anaesthesia, 1997, 7, 5-11.	1.1	183
78	Recommended use of morphine in neonates, infants and children based on a literature review: Part 2–Clinical use. Paediatric Anaesthesia, 1997, 7, 93-101.	1.1	135
79	The mu ₁ and mu ₂ opioid receptor binding of ketobemidone, norketobemidone and 3â€dimethylaminoâ€1,1â€diphenylbutene. Basic and Clinical Pharmacology and Toxicology, 1996, 79, 103-104.	0.0	4
80	Stereoselective Pharmacokinetics of Methadone in Chronic Pain Patients. Therapeutic Drug Monitoring, 1996, 18, 221-227.	2.0	120
81	The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine. Life Sciences, 1994, 56, 45-50.	4.3	156
82	Enhanced transdermal delivery of ketobemidone with prodrugs. International Journal of Pharmaceutics, 1992, 84, 253-260.	5.2	6
83	Saliva-catalyzed hydrolysis of a ketobemidone ester prodrug: Factors influencing human salivary esterase activity. International Journal of Pharmaceutics, 1992, 88, 221-227.	5.2	9
84	Ketobemidone prodrugs for buccal delivery: Prediction of the extent of saliva-catalyzed hydrolysis of various ester prodrugs under simulated in vivo conditions. International Journal of Pharmaceutics, 1992, 88, 229-235.	5.2	6
85	Enhanced delivery of ketobemidone through porcine buccal mucosa in vitro via more lipophilic ester prodrugs. International Journal of Pharmaceutics, 1992, 88, 237-242.	5.2	22
86	Buccal absorption of ketobemidone and various ester prodrugs in the rat. International Journal of Pharmaceutics, 1992, 88, 243-250.	5.2	6
87	Utilization of prodrugs to enhance the transdermal absorption of morphine. International Journal of Pharmaceutics, 1991, 71, 105-116.	5.2	29